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Introduction
Aldosterone is a mineralocorticoid hormone, whose effects 
are mediated by the binding to the mineralocorticoid 
receptors (MR), which are located in both epithelial and 
non-epithelial tissues.1,2 In the kidney, aldosterone acts not 
only on distal tubule epithelial cells, where it leads to 
sodium reabsorption and potassium excretion, but also on 
mesangial cells, podocytes, fibroblasts, and on glomerular 
vascular cells.3 In recent years there has been a paradigm 
shift in our understanding of aldosterone actions,3 which 
go far beyond sodium and potassium transport in the renal 
tubule and involve the ability of this hormone to modulate 
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Objective: Experimental evidence suggests that aldosterone directly contributes to organ damage by promoting 
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the local renin–angiotensin system (RAS),4,5 generate 
reactive oxygen species,6 and promote fibrosis.7
It has been shown that there is a correlation between 
kidney damage and circulating aldosterone,8–10 which 
could be due to aldosterone pro-oxidative, pro-inflammatory, 
and profibrotic effects, overall leading to glomerulosclero-
sis and tubulointerstitial fibrosis.3 This is consistent with 
experimental studies showing that MR antagonists, such as 
spironolactone and eplerenone, protect against progressive 
renal injury.11–13
Although it is abundantly clear that aldosterone causes 
renal damage, it has not been fully elucidated yet how this 
hormone affects the glomerulus and whether it could dam-
age the glomerular filtration barrier. Based on these obser-
vations, here we studied: (i) to what extent the glomerular 
permeability to albumin is affected by aldosterone; (ii) 
what are aldosterone molecular targets in isolated glomer-
uli (focusing on slit diaphragm components, local RAS 
mediators, pro-oxidative and profibrotic molecules), and 
(iii) whether aldosterone-induced changes are due to the 
binding to MR receptors.
Materials and methods
Animal model and experimental protocol
To evaluate aldosterone effects, the animal model that we 
chose was that of uninephrectomized, high-salt diet fed 
rats infused with aldosterone.8 This is a well-established 
animal model to study aldosterone effects,8 where both 
uninephrectomy and salt accelerate aldosterone-induced 
kidney damage. Several works have in fact demonstrated 
that salt and aldosterone synergistically contribute to renal 
impairment.14–16 Moreover, to discriminate the contribu-
tion of salt to glomerulosclerosis development, we rand-
omized the rats to either salt or aldosterone, or both. Based 
on these premises, 75 wild-type male Wistar rats, weighing 
250 g, underwent left uninephrectomy at baseline and 
were randomized to 5 different groups one week after. A 
total of 15 rats were fed with a 0.2% NaCl diet, considered 
the control diet (CNT), 15 rats were fed with a 1.2% NaCl 
diet, considered the high-salt diet (SALT), 15 rats were fed 
with a 0.2% NaCl diet and treated with aldosterone at a 
dose of 72 μg/kg/day (ALDO), 15 rats were fed with a 
1.2% NaCl diet and treated with aldosterone 
(ALDO+SALT), and 15 rats were fed with a 1.2% NaCl 
diet and treated with aldosterone and its antagonist 
eplerenone at a dose of 100 mg/kg/day (EPL). All the rats 
were fed with the Harlan Teklad 18% Protein Global Diet 
(Harlan Laboratories, Cat#2018), which contains 0.2% 
NaCl, 44.2% carbohydrates, 18.6% proteins, 18.2% fibers, 
and 6.2% fat. The rats of the SALT and ALDO+SALT 
groups had also the 1.2% NaCl solution to drink. 
Aldosterone was infused using an Alzet 2004-osmotic 
minipump (Alzet 2ML4model; AzaCorp, Palo Alto, CA, 
USA) and its dose was chosen taking into account what 
has been published previously.8 Eplerenone (Sigma, 
Cat#E6657) was administered incorporated into the Harlan 
Teklad 18% rodent diet at a concentration of 1.2 mg/g of 
chow (∼100 mg/kg/day). Previous works have demon-
strated the stability and efficacy of this dose of eplerenone 
incorporated into the diet.8,14 All the rats were then fol-
lowed for 4 weeks. At the end of the study, systolic blood 
pressure (SBP) was assessed by tail cuff plethysmography, 
and the rats were then placed in individual metabolic cages 
for 24 hours so that water intake could be recorded and 
total urine output collected. After performing these proce-
dures the animals were sacrificed, and bloods and kidneys 
were collected for biochemical, morphological, and 
molecular analyses. The rats were housed at the animal 
house of Trieste University and were studied according to 
Institutional guidelines.
This study was carried out in strict accordance with the 
recommendations in the Guide for the Care and Use of 
Laboratory Animals of the National Institutes of Health. A 
committee of the Italian Health Ministry approved the 
experimental protocol (permit number: prot 85 pos II/9 
10/02/2006). The animals were anesthetized by intraperi-
toneal injection of 2,2,2-tribromoethanol (Sigma Chemical, 
St Louis, MO, USA), at a dose of 25 mg/100 g of body 
weight. Buprenorphine (Temgesic, Reckitt Benckiser) was 
used as analgesic and was injected subcutaneously at a 
dose of 0.05 mg/kg the day of the intervention and at a 
dose of 0.025 mg/kg the day after. All efforts were made to 
minimize suffering.
General parameters and biochemical data
Body weight, relative kidney mass (kidney weight/body 
weight), SBP, daily water intake, daily urinary volume, 
daily sodium excretion, AER (albumin excretion rate), 
serum potassium, creatinine, and aldosterone were meas-
ured at the end of the study in all the rats. Urinary sodium, 
serum potassium, and creatinine were assessed by autoan-
alyzer. Urinary AER was measured by ELISA (Bethyl 
Laboratories, IMTEC Diagnostics, Antwerp, Belgium). 
Serum aldosterone was determined by EIA (DRG diagnos-
tics international, Marburg, Germany). Urinary nephrin 
was measured by ELISA (Exocell, Philadelphia, USA).
Assessment of glomerular albumin permeability
A total of 18–20 glomeruli were isolated from half kidney 
by standard sieving technique in media containing 50 g/L 
of bovine serum albumin (BSA) in PBS as an oncotic 
agent. Half of them were used for albumin permeability 
(Palb) assessment and half for RNA extraction. The glo-
meruli that were used for Palb assessment were incubated 
for 10 min at 37°C and then transferred to a glass coverslip 
where they were videotaped after a passage from a media 
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containing 50 g/L of BSA to a media containing 10 g/L of 
BSA. This media change creates an oncotic gradient across 
the basement membrane, resulting in a glomerular volume 
change (ΔV = (Vfinal – Vinitial)/Vinitial), which we measured 
off-line by a video-based image analysis program. In par-
ticular, since the computer program allows to determine 
the average glomerular radius in a two-dimensional space, 
the glomerular volume can be calculated by the formula 
V = 4/3πr3. Then σalb, which expresses the degree of mem-
brane permeability or leakiness, can be calculated by the 
formula
(σalb) = (ΔV)experimental/(ΔV)control,
and Palb, which refers to the movement of albumin subse-
quent to water flux, can be calculated by the formula 
1 − σalb.17
Kidney structural features
Two coronal 3 μm paraffin kidney sections were stained 
with hematoxylin-eosin, for tubular and glomerular area 
measurement, as described previously,18 and with periodic 
acid-Schiff, for mesangial matrix score assessment. The 
amount of mesangial matrix was scored with a range from 0 
to 4 (0 is for no change; 1 is for changes affecting <25%; 
2 is for changes affecting 25–50%; 3 is for changes 
affecting 50–75%; 4 is for changes affecting >75% of the 
glomerulus). 
Gene expression quantification by qRT-PCR
A total of 3 μg of RNA extracted from isolated glomeruli 
were used to synthesize cDNA with Superscript First 
Strand synthesis system for qRT-PCR (Gibco BRL, Grand 
Island, NY, USA), as previously described.19,20 Gene 
expression was analyzed by real-time qRT-PCR using the 
TaqMan system based on real-time detection of accumu-
lated fluorescence (ABI Prism 7900 HT, Perkin-Elmer Inc, 
Foster City, CA, USA). In order to control for variation in 
the amount of cDNA available in the samples, gene expres-
sion of the target sequence was normalized in relation to 
the expression of an endogenous control, 18s ribosomal 
RNA, and then reported as arbitrary units compared to the 
level of expression in untreated control, which were given 
an arbitrary value of 1. In particular, we analyzed the glo-
merular gene expression of ACE (angiotensin-converting 
enzyme), ACE2 (angiotensin-converting enzyme 2), ANP 
(atrial natriuretic peptide), CD2AP (CD2-adaptor protein), 
CTGF (connective tissue growth factor), CuZnSOD (cop-
per zinc superoxide dismutase), iNOS (inducible nitric 
oxide synthase), MMP-9 (matrix metallopeptidase-9), 
MnSOD (manganese superoxide dismutase), nephrin, 
NOX4 (NADPH oxidase 4), podocin, and USP2 (ubiqui-
tin-specific protease 2). For probe and primers sequences, 
see Supplementary Table 1 online.
Immunostainings
Glomerular ACE, ACE2, ANP (atrial natriuretic peptide), 
CTGF, and nitrotyrosilated proteins were quantified by 
immunostainings on 4 μm paraffin kidney sections. Kidney 
sections were incubated with the following primary anti-
bodies: mouse anti-ACE (Chemicon, Temecula, CA, USA, 
dilution 1:100); goat anti-ACE2 (R&D Systems, 
Minneapolis, MN, USA, dilution 1:100); rabbit anti-ANP 
(Millipore, Billerica, MA, USA, dilution 1:200), rabbit 
anti-CTGF (Abcam, Cambridge, UK, dilution 1:200), rab-
bit anti-nitrotyrosine (Upstate, Lake Placid, NY, USA, 
dilution 1:100). For more details on these primary antibod-
ies, see Supplementary Table 2 online. Biotinylated immu-
noglobulins (Vector Laboratories, Burlingame, CA, USA), 
were diluted 1:500 for ACE and ACE2, and 1:200 for ANP, 
CTGF, and nitrotyrosine and applied as secondary anti-
bodies. Sections were counterstained with either Aniline 
blue (Ventana, France) or hematoxylin. A total of three 
sections per animal were analyzed, where a minimum of 
20 glomeruli per section were counted. The percentage 
area occupied by the staining was calculated within the 
glomeruli. The results were expressed as the percentage of 
positive staining per glomerulus, i.e. percentage stained 
area.
Statistical analysis
The data were evaluated by analysis of variance (ANOVA) 
calculated using Statview 512 software for Apple 
Macintosh computer (Brainpower, Calabasas, CA, USA). 
Mean comparisons were performed by Fisher least signifi-
cant difference method (post-hoc test). Linear regression 
analysis was used for testing two variable relationships. 
Results were expressed as mean ± SEM, unless otherwise 
specified. The criterion for statistical significance was p < 
0.05.
Results
General parameters and biochemical data
Salt led to a significant increase in water intake, urinary 
volume, and sodium urinary excretion over 24 hours com-
pared to the controls (Table 1). Aldosterone infusion sig-
nificantly raised blood pressure levels and reduced serum 
potassium. Hypertension and hypokalemia were even 
greater when aldosterone was administered in combination 
with the salt diet and were significantly reduced by 
eplerenone, as shown in Table 1. In our study, aldosterone 
levels increased by 3.6 times in the rats infused with it, 
mimicking what is seen in patients with idiopathic hyper-
aldosteronism or aldosterone-producing adenomas where 
aldosterone levels increase by 2.67–3.82 times as com-
pared to patients with essential hypertension.21
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Renal structural features
Both salt and aldosterone led to kidney and tubular hyper-
trophy, as compared to the controls (Table 2). These effects 
were accentuated by combining salt to aldosterone, 
whereas they were blunted by eplerenone. Only aldoster-
one infusion, though, led to glomerular hyperthropy, which 
was significantly more pronounced in the high-salt diet fed 
rats, whilst it was reduced by eplerenone (Table 2). 
Consistent with these changes, aldosterone infusion only 
led to glomerular hypercellularity and to mesangial expan-
sion, which corresponds to the dark pink staining that can 
be seen in Figure 1 and whose score is reported in Table 2. 
These changes were more pronounced in the high-salt diet 
fed rats, where they were partially reduced by eplerenone.
Aldosterone and the glomerular filtration 
barrier
Aldosterone-induced glomerular structural changes 
(hypertrophy and mesangial expansion) were associated 
with a significant increase in glomerular Palb and AER 
(Table 2). In particular, there was a significant correlation 
between glomerular Palb and both glomerular hypertrophy 
(r = 0.550; p < 0.001) and AER (r = 0.516; p < 0.01). 
Having said that, we did not find any change in the glo-
merular gene expression of nephrin, podocin, CD2AP, and 
USP2 between the groups studied (data not shown). 
Moreover, urinary nephrin was almost undetectable in the 
groups studied (data not shown).
Glomerular renin–angiotensin system
The gene expression of ACE, ACE2, and ANP was meas-
ured in the glomeruli of all the groups of rats, where we 
found that salt and aldosterone significantly upregulated 
ACE and downregulated ACE2 gene and protein expres-
sion (Figure 2). Similarly to ACE2, also ANP was signifi-
cantly downregulated by aldosterone (Figure 2). All these 
changes were abolished by eplerenone (Figure 2).
Glomerular pro-oxidative and profibrotic 
changes
Since the generation of oxidative stress and the balance 
between production and degradation of extracellular matrix 
play an important role in aldosterone-driven kidney dam-
age,3 we decided to evaluate the glomerular expression of 
Table 1. General parameters and biochemical data.
CNT SALT ALDO ALDO+SALT EPL
BW (g) 326.6±5.7 319.7±11.3 326.0±4.2 321.4±5.7 321.2±6.9
SBP (mmHg) 117.8±1.6 116.6±2.0 154.7±1.6* 168.8±2.1*† 133.3±2.4*‡
Water intake (ml/100g BW) 6.8±0.8 16.5±1.1* 8.6±0.8 18.5±1.7* 13.9±1.2*
Urinary volume (ml/100g BW) 10.1±0.3 31.0±2.7* 13.7±1.3 42.1±5.1* 32.0±3.1*
Urinary sodium (mEq/100g BW/day) 0.4±0.1 3.0±0.2* 0.5±0.1 3.5±0.4* 3.4±0.3*
Serum potassium (mEq/L) 6.1±0.2 6.5±0.2 3.9±0.2* 3.3±0.1*† 4.6±0.2*‡
Serum aldosterone (pg/mL) 249±27 213±32 988±117* 978±100* 805±74*
Data are expressed as mean ± SEM; * p < 0.05 vs. CNT; † p < 0.05 vs. ALDO; ‡ p < 0.05 vs. ALDO+SALT. CNT is 0.2% NaCl diet; SALT is 1.2% 
NaCl diet; ALDO is aldosterone and 0.2% NaCl diet; ALDO+SALT is aldosterone and 1.2% NaCl diet; EPL is aldosterone, eplerenone, and 1.2% 
NaCl diet; BW is body weight; SBP is systolic blood pressure.
Table 2. Glomerular structural and functional features.
CNT SALT ALDO ALDO+SALT EPL
Kidney structural features
Renal mass (mg KW/g BW) 3.85±0.09 4.13±0.05* 4.51±0.06* 5.63±0.09*† 4.66±0.09*‡
Tubular area (µm2) 1403±19.9 1473±25.8* 1479±22.1* 1738±26.2*† 1380±17.8*‡
Glomerular area (µm2) 8112±77 8209±84 8852±101* 9633±136*† 9201±98*‡
Mesangial matrix score 0.5 ± 0.01 0.5 ± 0.01 2.5 ± 0.02* 3.0 ± 0.04*† 2.2 ± 0.15*‡
Glomerular functional features
Palb (arbitrary units) 0.08±0.03 0.11±0.07 0.34±0.08 0.53±0.05* 0.27±0.06*‡
AER (mg/24 h) 0.62±0.07 0.55±0.1 0.80±0.06 3.19±0.41* 2.03±0.69*‡
Creatinine (mg/dL) 0.44±0.02 0.42±0.01 0.38±0.02 0.38±0.02 0.38±0.01
Data are expressed as mean ± SEM; * p < 0.05 vs. CNT; † p < 0.05 vs. ALDO; ‡ p < 0.05 vs. ALDO+SALT. CNT is 0.2% NaCl diet; SALT is 1.2% 
NaCl diet; ALDO is aldosterone and 0.2% NaCl diet; ALDO+SALT is aldosterone and 1.2% NaCl diet; EPL is aldosterone, eplerenone, and 1.2% 
NaCl diet; KW is kidney weight; BW is body weight; Palb is albumin permeability; AER is albumin excretion rate.
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Figure 1. Effect of aldosterone, alone or in combination with salt, on mesangial matrix expansion. Representative periodic acid-
Shiff (PAS) stained sections of kidneys (original magnification 25×): (a) CNT; (b) SALT; (c) ALDO; (d) ALDO+SALT; (e) EPL.  
CNT is 0.2% NaCl diet; SALT is 1.2% NaCl diet; ALDO is aldosterone and 0.2% NaCl diet; ALDO+SALT is aldosterone and  
1.2% NaCl diet; EPL is aldosterone, eplerenone, and 1.2% NaCl diet.
Figure 2. Effect of aldosterone, alone or in combination with salt, on glomerular RAS. (a) Glomerular ACE, ACE2, and ANP 
messenger RNA expression, reported as relative gene units. Data are expressed as mean ± SEM. * p < 0.05 vs. CNT; ‡ p < 0.05 vs. 
ALDO+SALT. (b) Glomerular ACE, ACE2, and ANP protein expression, reported as percentage stained area. Data are expressed as 
mean ± SEM. * p < 0.05 vs. CNT; † p < 0.05 vs. ALDO; ‡ p < 0.05 vs. ALDO+SALT. (c–q) Representative ACE (upper panel), ACE2 
(middle panel), and ANP (lower panel) immunostained sections of glomeruli (original magnification 25×): (c, h, m) CNT; (d, i, n) SALT; 
(e, j, o) ALDO; (f, k, p) ALDO+SALT; (g, l, q) EPL.
CNT is 0.2% NaCl diet; SALT is 1.2% NaCl diet; ALDO is aldosterone and 0.2% NaCl diet; ALDO+SALT is aldosterone and 1.2% NaCl diet;  
EPL is aldosterone, eplerenone, and 1.2% NaCl diet; ACE is angiotensin-converting enzyme; ACE2 is angiotensin-converting enzyme 2; ANP is  
atrial natriuretic peptide, RAS is renin-angiotensin system.
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molecules involved in these processes. In particular, we 
focused on CuZnSOD, iNOS, MnSOD, and NOX4 as well 
as on CTGF and MMP-9, whose gene expression was 
measured in the glomeruli previously isolated from the kid-
neys of all the groups of rats. With respect to oxidative stress 
generation, although the glomerular expression of MnSOD 
and NOX4 did not change between the groups studied 
(data not shown), CuZnSOD, which is an anti-oxidant, and 
iNOS, which is a pro-oxidant, were significantly down- 
and upregulated, respectively, in the glomeruli of the 
ALDO+SALT rats (Figure 3). The staining for nitrosylated 
proteins, which are a marker of oxidative stress, showed 
that there was a significant increase in glomerular nitroty-
rosine in the SALT, ALDO, and ALDO+SALT groups, and 
that eplerenone reduced it significantly (Figure 3).
In terms of profibrotic changes, aldosterone combined 
with salt significantly upregulated CTGF and downregu-
lated MMP-9 glomerular gene expression (Figure 4). This 
was consistent with CTGF immunostaining showing a sig-
nificant increase of this protein expression in the glomeruli 
of the rats treated with aldosterone alone or in combination 
with salt (Figure 4). Eplerenone significantly reduced 
these effects (Figure 4).
Discussion
This work aimed at investigating the glomerular effects of 
aldosterone, alone and in combination with salt, and we 
found that aldosterone damages the glomerulus, where it 
induces structural and functional changes. In particular, 
this is the first study where the glomerular permeability to 
albumin has been measured in aldosterone-infused rats. 
Here we found that aldosterone significantly increased the 
glomerular permeability to albumin and albuminuria, 
which were positively correlated, in line with the concept 
that albuminuria is related to an alteration of glomerular 
permeability. To test the hypothesis that aldosterone 
increases glomerular permeability by damaging the slit 
diaphragm,22–23 we studied three important proteins of the 
slit diaphragm, which are nephrin, podocin, and CD2AP, 
whose mutations have been linked to nephrotic syndrome 
development.24 In addition, we also quantified USP2, 
which seems to play a role in mesangial cell proliferation 
during glomerulonephritis.25 Contrary to what has been 
previously reported,22 we found no changes in the glomer-
ular expression of these genes. Likewise, urinary nephrin 
was almost undetectable, suggesting that there was no 
podocyte loss. A first explanation to this negative data may 
be ascribed to the percentage of salt of our diet as com-
pared to the 8% salt diet used by Shibata et al.,22 given that 
the 8% salt diet usually worsens glomerular damage as 
compared to the 1.2% salt diet.18 Secondly, it is also pos-
sible that aldosterone needs a much longer period of time 
before it damages the podocytes,26 consistent with the 
observation that the downregulation of slit diaphragm pro-
teins correlates with the stage of glomerular damage.27 In 
Figure 3. Effect of aldosterone, alone or in combination with salt, on glomerular oxidative stress. (a) Glomerular CuZnSOD and 
iNOS messenger RNA expression, reported as relative gene units. Data are expressed as mean ± SEM. * p < 0.05 vs. CNT; ‡ p < 
0.05 vs. ALDO+SALT. (b) Glomerular nitrotyrosine protein expression, reported as percentage stained area. Data are expressed 
as mean ± SEM. * p < 0.05 vs. CNT; # p < 0.05 vs. SALT; † p < 0.05 vs. ALDO; ‡ p < 0.05 vs. ALDO+SALT. (c–g) Representative 
nitrotyrosine immunostained sections of glomeruli (original magnification 25X): (c) CNT; (d) SALT; (e) ALDO; (f) ALDO+SALT; 
(g) EPL. CNT is 0.2% NaCl diet; SALT is 1.2% NaCl diet; ALDO is aldosterone and 0.2% NaCl diet; ALDO+SALT is aldosterone 
and 1.2% NaCl diet; EPL is aldosterone, eplerenone, and 1.2% NaCl diet; CuZnSOD is copper zinc superoxide dismutase; iNOS is 
inducible nitric oxide synthase.
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the third place, proteinuria does not only rely on podocyte 
changes,28,29 but it can also be ascribed to abnormalities of 
endothelium and basement membrane.30
Consistent with the concept that a high-salt diet has a 
detrimental effect on kidney function,18 and that it worsens 
the glomerular changes due to aldosterone,15 here we 
found that the ALDO+SALT group displayed the highest 
degree of glomerular permeability to albumin and protein-
uria. The fact that salt worsens the effect of aldosterone is 
due to the ability of salt to cause paradoxical MR activa-
tion through Rac1,31 which modulates MR activity, as the 
inhibition of the Rac-1-MR cascade by eplerenone amelio-
rates salt-mediated kidney injury.16 Here we found that 
eplerenone reduced most, but not all, aldosterone-driven 
effects. This suggests that mechanisms other than MR acti-
vation are involved in the aldosterone/salt-induced 
nephropathy, such as the non-genomic effects that aldos-
terone can exerts in the absence of MR activation.32 
Moreover, as suggested by other authors,33 the reason 
underlying the discrepancy between the degree of aldos-
terone-induced renal damage and the modest effect of 
eplerenone is that aldosterone levels may be too high to be 
efficiently counteracted by MR antagonists.
In recent years there has been a paradigm shift in our 
understanding of aldosterone actions, which go far beyond 
sodium and potassium transport in the renal tubule and 
involve the ability of this hormone to stimulate the local 
RAS,4,5 generate reactive oxygen species,6 and promote 
fibrosis,7 whereby it leads to organ damage.7 It is well 
known that the activation of the RAS is involved in the 
development and progression of kidney disease, as its 
blockade is one of the most efficient ways to reduce pro-
teinuria as well as to delay renal insufficiency.3 Such 
blockade has traditionally focused on inhibiting the syn-
thesis of angiotensin (Ang) II and/or preventing activation 
of Ang II type 1 receptor. Nevertheless, the degradation of 
Ang II is also important,34 and the major enzyme that con-
verts Ang II to Ang 1-7 is ACE2.35 So, it is the balance 
between ACE and ACE2 that is currently considered criti-
cal for the activation of renal RAS.36,37 Having said that, 
the second novel aspect of this work is that we show the 
effect that aldosterone, alone and in combination with salt, 
has on ACE2 glomerular expression in vivo. Here salt and 
aldosterone significantly reduced ACE2 expression, while 
ACE increased, leading to an upregulation of ACE/ACE2 
ratio, which is in line with previous observations.38,39 Now, 
based on recent experimental evidence,40–42 it is possible to 
speculate that the glomerular changes that follow aldoster-
one infusion are partly relying on ACE2 downregulation. 
First of all, ACE2 deficiency/inhibition alone can increase 
glomerular ACE gene and protein expression,18,43 with a 
subsequent increase of local Ang II. Secondly, ACE2 
downregulation contributes to aldosterone-induced glo-
merular changes, as ACE2 deficiency has been found 
Figure 4. Effect of aldosterone, alone or in combination with salt, on glomerular profibrotic changes. (a) Glomerular CTGF and 
MMP-9 messenger RNA expression, reported as relative gene units. Data are expressed as mean ± SEM. * p < 0.05 vs. CNT; ‡ p < 
0.05 vs. ALDO+SALT. (b) Glomerular CTGF protein expression, reported as percentage stained area. Data are expressed as mean 
± SEM. * p < 0.05 vs. CNT; ‡ p < 0.05 vs. ALDO+SALT. (c–g) Representative CTGF immunostained sections of glomeruli (original 
magnification 25×): (c) CNT; (d) SALT; (e) ALDO; (f) ALDO+SALT; (g) EPL. CNT is 0.2% NaCl diet; SALT is 1.2% NaCl diet; 
ALDO is aldosterone and 0.2% NaCl diet; ALDO+SALT is aldosterone and 1.2% NaCl diet; EPL is aldosterone, eplerenone, and 
1.2% NaCl diet; CTGF is connective tissue growth factor; MMP-9 is matrix metallopeptidase.
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associated with pro-oxidative, pro-inflammatory, and 
profibrotic glomerular changes.40–42 It should be noted that 
ACE2 protects the kidney not only by Ang II degradation, 
but also by Ang 1-7 and ANP generation,40 which are both 
renoprotective.44–46 In line with the concept that ACE2 
regulates ANP renal production,40 here we found that 
aldosterone significantly reduced also ANP glomerular 
expression, which is the third novel aspect of this paper.
Besides RAS activation, which interacts with aldosterone 
in inducing tissue damage, aldosterone led to pro-oxidative 
and profibrotic changes, which were reduced by eplerenone 
and can also underpin the glomerular changes that we 
observed. On one hand, reactive oxygen species (ROS) pro-
duction might have in fact contributed to the glomerular 
functional changes induces by aldosterone, as superoxide 
and hydroxyl radicals increase the glomerular permeability 
to albumin (possibly by lipid peroxidation of cell membrane 
cytoskeleton), and this is reversed by blocking these media-
tors with scavengers.47 On the other hand, CTGF upregula-
tion could also explain glomerular structural and functional 
changes. CTGF, which is not normally expressed in the 
healthy kidney, is induced in the early stages of renal dis-
eases,48 and its levels correlate with the severity and progres-
sion of renal fibrosis.49 Interestingly, it has been shown that 
CTGF induces mesangial cell cycle arrest, mesangial cell 
hypertrophy, and mesangial matrix expansion in renal non-
epithelial cells,50 as well as that CTGF can damage the slit 
diaphragm.51 Moreover, treatment of diabetic mice with 
CTGF antisense oligonucleotide attenuates albuminuria.52
In conclusion, our work further characterizes the effects 
of aldosterone on the glomerulus. Here we show that aldos-
terone infusion induces glomerular hypertrophy, mesangial 
expansion, and it increases the glomerular permeability to 
albumin. These aldosterone-induced glomerular effects are 
likely to be mediated by the binding to the mineralocorticoid 
receptors, as eplerenone reverses them. In particular, we 
speculate that some of the aldosterone effects might depend 
on RAS activation, as aldosterone significantly reduced 
ACE2, increased the ACE/ACE2 ratio, and decreased ANP, 
which were partly reversed by eplerenone. Besides RAS 
activation, aldosterone led also to local oxidative stress gen-
eration and profibrotic changes, which altogether might have 
contributed to the induction of glomerular damage.
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